Skip to content

The Clinical and Radiographic Outcomes of a 3D-printed Patient-specific Biomimetic Bone Substitute in Maxillofacial Indications: an Interventional, Multi-centred, Open-label, Post-market Clinical Investigation.

The Clinical and Radiographic Outcomes of a 3D-printed Patient-specific Biomimetic Bone Substitute in Maxillofacial Indications: an Interventional, Multi-centred, Open-label, Post-market Clinical Investigation.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04773847
Enrollment
20
Registered
2021-02-26
Start date
2021-04-30
Completion date
2022-10-31
Last updated
2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Regeneration

Brief summary

The purpose of the study is to evaluate the clinical and radiographic outcome of MimetikOss 3D as a patient-specific bone substitute in regeneration of osseous defects in several maxillofacial indications. The primary objective is to evaluate the capacity of MimetikOss 3D to perform bone substitute requirements, i.e long-term regeneration of bony tissue in complex defects without detrimental resorption. The secondary main objectives are to assess the versatility of MimetikOss 3D by the variety of maxillofacial sites regenerated and the surgical technique improvement (in terms of surgery duration, blood loss, ease-of-use of the product and surgeon satisfaction).

Interventions

PROCEDURESurgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.

Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.

Sponsors

Mimetis Biomaterials S.L.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Since the studied medical device is a custom-made product, only one group is considered.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female age 18 years or over at the time of inclusion into the study; * Ability to obtain written informed consent from the recipient; * Patients in need of craniomaxillofacial bone regeneration; * Ability and capacity to comply with the procedures described in the protocol, including responding to simple questionnaires either by the recipient in person or by a next relative (spouse, parent) who lives with the recipient; * Patients with good general hygiene; * Radiographic exam allowing a complete observation of the osseous defect; * Mimetis approval of the feasibility.

Exclusion criteria

* Active tumour; * Passive tumour with cancer recurrence within 10 years; * Practice of intensive contact sport exercise during the clinical trial duration; * Concomitant participation in other clinical trials; * Women of childbearing potential who are, or plan to become, pregnant during the time of the study; * Women who are breastfeeding; * Alcohol or drug abuse as noted in subject records or in subject history; * Patients with a medical condition that may compromise the healing process or history of systemic diseases that would contraindicate the surgical treatment or any other disease that might have an influence on the involved tissues, such as: severe metabolic disorders, osteogenesis imperfecta, osteoporosis, infectious and degenerative bone diseases, immunodeficiency (congenital or acquired), autoimmune disease, Osler-Weber-Rendu syndrome, unbalanced diabetes, transient hypercalcemia, allergic disposition to phosphate calcium components, titanium or collagen etc; immunosuppressive therapy, steroid therapy, heparin treatment, corticoid treatment, treatments that interfere in the calcium-phosphate metabolism, bisphosphonate intake, Paclitaxel treatment, methotrexate medication etc); * Acute and chronic infections in the surgery area (e.g. soft tissue infections, inflammatory and bacterial osteopathy, osteomyelitis) and / or mucosal diseases in the areas to be treated; * In case of intraoral surgery, heavy smokers (\>10 cigarettes) excluded; * Inability to return for follow up visits.

Design outcomes

Primary

MeasureTime frame
Geometric evolution of the grafted volume through radiological evaluation6 months post-surgery

Secondary

MeasureTime frameDescription
Versatility of MimetikOss 3D patient-specific bone substitute12 months post-surgeryMimetikOss 3D can be implanted to regenerate osseous defect from different indications of the maxillofacial area (dental area, jaw and maxilla reconstruction, zygomatic reconstruction and/or chin reconstruction for instance).
Incidence of serious adverse events and adverse eventsduring the surgery / 6 months post-surgery / 12 months post-surgery
Bone union observation12 months post-surgery
Surgical technique improvement in terms of accuracy of MimetikOss 3D design and positioningdirectly after the surgery / 6 months post-surgery / 12 months post-surgery
Geometric evolution of the grafted volume through radiological evaluation12 months post-surgery
Surgical technique improvement in terms of blood loss measurementduring the surgery
Surgical technique improvement in terms of surgeon satisfaction12 months post-surgery
Aesthetic evaluation by visual observation of the symmetry of the face, pictures and/or irregular contours prosthetic palpable (if applicable)directly after the surgery / 6 months post-surgery / 12 months post-surgery
Surgical technique improvement in terms of total surgery duration and duration of implantation of MimetikOss 3Dduring the surgery

Contacts

Primary ContactEmilie Thorel
emilie.thorel@mimetis.es+33672121897
Backup ContactEmilie Thorel
cr@mimetis.es

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026